UniFocus IAS ( UNIFOCUS UNIVERSAL )

The Indian Navy inducteded  Mahendragiri (F38), the sixth Project 17A indigenous stealth frigate, into its Eastern Fleet at Visakhapatnam on 11 Jul 2026. It was designed in-house by the Indian Navy's Warship Design Bureau (WDB) and built by Mazagon Dock Shipbuilders Limited (MDL), Mumbai. It i ncorporates advanced stealth features, enhanced survivability, reduced radar signature, and a high degree of automation, the warship is designed to undertake full spectrum of maritime operations in all dimensions of naval warfare. It comprises of  75 percent indigenous content. It is  equipped with an advanced suite of indigenous and state-of-the-art weapons, sensors, and electronic warfare systems, enabling her to effectively undertake anti-air, anti-surface, and anti-submarine operations. The ship is also capable of maritime security operations, Search and Rescue missions, Humanitarian Assistance and Disaster Relief (HADR), and sustained deployments across the Indian Ocean Regi...

Resolution 62/27 on “Human rights and neglected tropical diseases” was adopted today by the Human Rights Council (HRC) at its sixty-second session in Geneva. The first ever HRC resolution dedicated to all neglected tropical diseases (NTDs) was adopted by consensus, after being put forward by six African countries where the burden of NTDs is significant; the group was led by Malawi, and included Burkina Faso, Gambia, Kenya, Morocco and the United Republic of Tanzania. Notably, the resolution identifies the underlying, structural and social determinants of NTDs, including “lack of access to safe water, sanitation, adequate housing, education and information”. Other important determinants cited are climate change, displacement due to natural disasters and conflicts.  The resolution also acknowledges the fact that some NTDs excessively affect women and girls as well as remote, underserved and mobile communities, and underlines the importance of disaggregated data collection and analysi...

Test Post

In a significant step towards strengthening the regulatory oversight of advanced and emerging medical technologies, the Central Government has amended the Drugs Rules, 1945 to bring Cell or Stem Cell derived products, Gene therapeutic products and Xenografts under the ambit of the Centrally License Approving Authority (CLAA) framework. Under the Drugs and Cosmetics Act, certain specified categories of critical drugs and biological products are under the joint regulatory supervision of the Central and State regulators. These include vaccines, large volume parenterals (IV solutions > 100 ml) and r-DNA based medicines. This set is being expanded with this amendment to cover additional emerging technologies. Cell or Stem Cell derived products e.g. such as stem cell-based regenerative treatments, CAR-T cell therapies have seen increasing use in treatment of blood cancers such as leukemias and lymphomas. Gene therapeutic products such as gene replacement and gene editing products have fou...